+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sitagliptin"

From
From
Diabetes Drug Intelligence Center 2012-2023 - Product Thumbnail Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • May 2024
  • Global
From
From
From
Global Anti-diabetic Drugs Market - Product Thumbnail Image

Global Anti-diabetic Drugs Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
From
From
From
US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 500 Pages
  • United States
From
From
From
From
From
From
From
From
Loading Indicator

Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease. Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders. Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more